The Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) drugs in development market research report provides comprehensive information on the therapeutics under development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva). Buy the report here.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) by eight companies/universities/institutes. The top development phase for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) is preclinical with four drugs in that stage. The Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) pipeline has eight drugs in development by companies and two by universities/ institutes. Some of the companies in the Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) pipeline products market are: La Jolla Pharmaceutical, Ipsen and Incyte.
The key targets in the Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) pipeline products market include Activin Receptor Type 1, Matrix Metalloproteinase 9, and Inhibin Beta A Chain.
The key mechanisms of action in the Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) pipeline product include Activin Receptor Type 1 Inhibitor with five drugs in Phase II. The Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) pipeline products include four routes of administration with the top ROA being Oral and two key molecule types in the Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) pipeline products market including Small Molecule, and Monoclonal Antibody.
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) overview
Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle tissue and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), which constrains movement. Symptoms include swellings in fibrous tissue, pain, fever, muscle ossification, and restricted movement of joints. Treatment includes surgery and medications to help relieve symptoms of FOP, such as pain and inflammation.
For a complete picture of Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.